Adc Therapeutics Sa Stock Current Valuation
| ADCT Stock | USD 1.61 0.09 5.29% |
Valuation analysis of ADC Therapeutics helps investors to measure ADC Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, ADC Therapeutics' Enterprise Value Over EBITDA is comparatively stable compared to the past year. Enterprise Value Multiple is likely to gain to 0.12 in 2025, despite the fact that Enterprise Value is likely to grow to (20.3 M). Fundamental drivers impacting ADC Therapeutics' valuation include:
Overvalued
Today
Please note that ADC Therapeutics' price fluctuation is dangerous at this time. Calculation of the real value of ADC Therapeutics is based on 3 months time horizon. Increasing ADC Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
ADC Therapeutics' intrinsic value may or may not be the same as its current market price of 1.61, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.61 | Real 1.41 | Target 8.4 | Hype 1.61 | Naive 1.54 |
The intrinsic value of ADC Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence ADC Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of ADC Therapeutics SA helps investors to forecast how ADC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of ADC Therapeutics more accurately as focusing exclusively on ADC Therapeutics' fundamentals will not take into account other important factors: ADC Therapeutics SA Company Current Valuation Analysis
ADC Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ADC Therapeutics Current Valuation | 5.95 M |
Most of ADC Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ADC Therapeutics SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ADC Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for ADC Therapeutics is extremely important. It helps to project a fair market value of ADC Stock properly, considering its historical fundamentals such as Current Valuation. Since ADC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ADC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ADC Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ADC Therapeutics SA has a Current Valuation of 5.95 M. This is 99.96% lower than that of the Communications Equipment sector and 99.87% lower than that of the Information Technology industry. The current valuation for all United States stocks is 99.96% higher than that of the company.
ADC Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ADC Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics of similar companies.ADC Therapeutics is currently under evaluation in current valuation category among its peers.
ADC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of ADC Therapeutics from analyzing ADC Therapeutics' financial statements. These drivers represent accounts that assess ADC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of ADC Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 2.1B | 1.6B | 300.1M | 135.6M | 156.0M | 148.2M | |
| Enterprise Value | 1.7B | 1.2B | 91.0M | (18.6M) | (21.4M) | (20.3M) |
ADC Fundamentals
| Return On Equity | -7.06 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (3.00) % | ||||
| Operating Margin | (1.93) % | ||||
| Current Valuation | 5.95 M | ||||
| Shares Outstanding | 96.69 M | ||||
| Shares Owned By Insiders | 20.64 % | ||||
| Shares Owned By Institutions | 63.17 % | ||||
| Number Of Shares Shorted | 5.3 M | ||||
| Price To Earning | 19.80 X | ||||
| Price To Book | 2.58 X | ||||
| Price To Sales | 2.20 X | ||||
| Revenue | 69.56 M | ||||
| Gross Profit | (59.85 M) | ||||
| EBITDA | (146.76 M) | ||||
| Net Income | (240.05 M) | ||||
| Cash And Equivalents | 376.78 M | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 124.38 M | ||||
| Debt To Equity | 2.75 % | ||||
| Current Ratio | 5.76 X | ||||
| Book Value Per Share | (1.78) X | ||||
| Cash Flow From Operations | (118.69 M) | ||||
| Short Ratio | 11.50 X | ||||
| Earnings Per Share | (2.39) X | ||||
| Price To Earnings To Growth | 0.74 X | ||||
| Target Price | 8.8 | ||||
| Number Of Employees | 273 | ||||
| Beta | 1.52 | ||||
| Market Capitalization | 155.67 M | ||||
| Total Asset | 354.78 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 268.62 M | ||||
| Current Asset | 1.11 B | ||||
| Current Liabilities | 288.7 M | ||||
| Net Asset | 354.78 M |
About ADC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ADC Therapeutics SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.